GlassScriptPhysician profile
Andre D Nunley
NPI 1922449180
$10,024.96
in general payments reported to CMS, 2019-2025
46 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,473 · 2022: $1,817 · 2023: $2,071 · 2024: $1,724 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,734.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,053.78 | 2021-2025 | |
| Abbvie INC. | $1,044.81 | 2021-2025 | |
| Novo Nordisk INC | $964.97 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $870.94 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $776.49 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.03 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $561.48 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $508.69 | 2021-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $361.24 | 2021-2025 | Steglatro, Verquvo, Capvaxive |
| Abbott Laboratories | $345.17 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $313.21 | 2021-2025 | Spravato, Xarelto |
| Antares Pharma, INC. | $246.75 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $233.99 | 2021-2022 | |
| Daiichi Sankyo INC. | $174.37 | 2021-2025 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $168.23 | 2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Nunley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.